Determinants of Erythrocyte Omega‐3 Fatty Acid Content in Response to Fish Oil Supplementation: A Dose–Response Randomized Controlled Trial

Background The erythrocyte membrane content of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which constitutes the omega‐3 index (O3I), predicts cardiovascular disease mortality. The amount of EPA+DHA needed to achieve a target O3I is poorly defined, as are the determinants of the O3I...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Heart Association 2013-12, Vol.2 (6), p.e000513-n/a
Main Authors: Flock, Michael R., Skulas‐Ray, Ann C., Harris, William S., Etherton, Terry D., Fleming, Jennifer A., Kris‐Etherton, Penny M.
Format: Article
Language:English
Subjects:
Administration, Oral
Adult
blood cell
Body Weight
Dietary Supplements
Docosahexaenoic Acids - administration & dosage
Docosahexaenoic Acids - blood
Dose-Response Relationship, Drug
Double-Blind Method
Drug Combinations
Drug Dosage Calculations
Eicosapentaenoic Acid - administration & dosage
Eicosapentaenoic Acid - blood
Erythrocytes - drug effects
Erythrocytes - metabolism
fatty acids
Female
fish oil
Healthy Volunteers
Humans
Male
metabolism
Middle Aged
Multivariate Analysis
nutrition
Original Research
Pennsylvania
Time Factors
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The erythrocyte membrane content of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which constitutes the omega‐3 index (O3I), predicts cardiovascular disease mortality. The amount of EPA+DHA needed to achieve a target O3I is poorly defined, as are the determinants of the O3I response to a change in EPA+DHA intake. The objective of this study was to develop a predictive model of the O3I response to EPA+DHA supplementation in healthy adults, specifically identifying factors that determine the response. Methods and Results A randomized, placebo‐controlled, double‐blind, parallel‐group study was conducted in 115 healthy men and women. One of 5 doses (0, 300, 600, 900, 1800 mg) of EPA+DHA was given daily as placebo or fish oil supplements for ≈5 months. The O3I was measured at baseline and at the end of the study. There were no significant differences in the clinical characteristics between the groups at baseline. The O3I increased in a dose‐dependent manner (P
ISSN:2047-9980
2047-9980
DOI:10.1161/JAHA.113.000513